Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Pharmaceutical earnings stories

Nov 6, 2026

GSK and Moderna settle patent dispute over COVID and RSV vaccines

GSK has settled lawsuits accusing Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, resolving a major intellectual property dispute between the two drugmakers.

Nov 6, 2026·2 sources
00

Sarepta halts enrollment in confirmatory Phase 3 trial of Elevidys

Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.

Nov 6, 2026·2 sources
00
Nov 5, 2026

Cigna raises 2026 profit outlook on insurance and specialty pharmacy strength

Cigna raised its annual profit forecast after beating third-quarter results, driven by gains in its specialty-pharmacy and health-services businesses, though its pharmacy benefits manager Express Scripts remains a drag.

Nov 5, 2026·4 sources
00
Nov 4, 2026

Novo Nordisk raises 2026 outlook for third time on strong Wegovy pill sales

Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.

Nov 4, 2026·4 sources
00
Nov 3, 2026

Amgen raises 2026 revenue forecast on strong cholesterol and cancer drug sales

Amgen raised its sales and profit forecast for the third time in 2026 after third-quarter sales rose 8%, led by cholesterol drug Repatha and newer medicines Imdelltra and Uplizna.

Nov 3, 2026·2 sources
00

Pfizer raises 2026 outlook on strong demand for non-Covid drugs

Pfizer raised its full-year profit and revenue outlook after third-quarter results beat estimates, driven by growing demand for newly launched and acquired medicines as Covid product sales decline.

Nov 3, 2026·4 sources
00

Bayer raises 2026 profit outlook on strong pharmaceutical demand

Bayer AG raised its annual profit outlook after better-than-expected third-quarter performance driven by demand for newer drugs in its pharmaceuticals business.

Nov 3, 2026·2 sources
00
Nov 2, 2026

Teva Pharmaceutical beats Q3 profit forecasts, raises 2026 revenue guidance

Israeli drugmaker Teva Pharmaceutical Industries reported third-quarter profit that exceeded analyst expectations, driven by strong sales of three branded medicines that offset declines in generic drugs. The company raised its full-year 2026 revenue estimates following the results.

Nov 2, 2026·3 sources
00
Oct 30, 2026

AbbVie raises annual profit forecast on strong immunology drug sales

AbbVie raised its full-year profit forecast after beating third-quarter expectations, driven by strong demand for its newer immunology and neuroscience drugs as the company navigates the Humira patent cliff.

Oct 30, 2026·2 sources
00
Oct 29, 2026

Eli Lilly raises revenue forecast on weight-loss drug demand

Eli Lilly raised its full-year revenue forecast by $5 billion and beat third-quarter profit estimates driven by booming demand for its injectable weight-loss drugs, particularly among older Americans.

Oct 29, 2026·2 sources
00
Oct 28, 2026

GSK shares fall after vaccine sales disappoint in Q3 results

GSK reported a drop in vaccine sales in its third quarter, sending shares down despite beating overall sales and profit expectations, as the UK drugmaker works to accelerate growth and prepare for patent expirations.

Oct 28, 2026·4 sources
00
Oct 27, 2026

Cipla misses Q2 profit forecast on US weakness, shares slip

Indian drugmaker Cipla reported second-quarter earnings that missed profit expectations due to weakness in its US business, causing its shares to decline. The disappointing results reflect challenges in the company's American operations.

Oct 27, 2026·1 source
00

Novartis raises profit guidance despite $1.9 billion drug trial setback

Novartis increased its full-year core profit outlook for the third time in 2026, driven by growth of new medicines, but took a $1.9 billion write-down for neuromuscular drug candidate del-desiran following trial failure.

Oct 27, 2026·2 sources
00
Jul 15, 2026

Johnson & Johnson beats earnings estimates on strength of Tremfya and Darzalex

Johnson & Johnson exceeded Wall Street estimates for second-quarter sales and profit, driven by strong demand for immunology drug Tremfya and cancer treatment Darzalex, offsetting erosion in other product lines.

Jul 15, 2026·1 source
00

Top claims

  • ▪GSK and Moderna settled all pending patent infringement lawsuits regarding Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV vaccine mResvia
  • ▪Moderna reported third-quarter 2026 total revenue of $1.313 billion, representing a 29% increase from $1.016 billion in the third quarter of 2025
  • ▪The U.S. Food and Drug Administration granted accelerated approval for Moderna's mFLUSIVA for adults aged 65 and older, contingent on a confirmatory efficacy study

People involved

Robert F. Kennedy Jr.

Subtopics

Pharmaceutical Industry9Corporate earnings7Cancer treatment4Cancer & Oncology3Cancer and Cancer Treatment3Eli Lilly3Novo Nordisk3Pharmaceutical patents3Clinical trials2Corporate restructuring2COVID-19 vaccines2Drug development2Drug Policy, Pricing & Approval2Generic drugs & biosimilars2Stock market performance2Zepbound2Accelerated approval pathways1Affordable Care Act1Affordable Care Act (ACA)1Autoimmune disease treatments1Cholesterol management1Clinical trial design1Corporate strategy1Drug safety1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories